Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Correction: Polymer Factory Sweden AB (publ) Interim Report Q2 2021

Correction of the previously disclosed press release; the MAR-label was added to the interim report in addition to being in the press release.The period in summary Second quarter, April-June 2021 · The company was listed on Spotlight Stock Market with first day of trading 7th April 2021. · A new CEO started 1st April 2021. · The loss for the period amounted to KSEK -922, of which KSEK 200 can be derived from IPO related activities. · Net sales for the period increased with 177% Q2. Year to date, January-June 2021 · The operating loss for the period amounted to KSEK -

The Global Change Award is Back, with New Scope

STOCKHOLM; August 25, 2021 – The world’s largest innovation challenge to transform the fashion industry is now open for applications. The Global Change Award 2022 is seeking early-stage innovations contributing to a planet positive fashion industry by addressing the earth’s global commons: land, water, oceans, climate and biodiversity. Winners get to share a grant of 1 million euro, provided by the H&M Foundation.The Global Change Award was initiated in 2015 by non-profit H&M Foundation, in collaboration with Accenture and the KTH Royal Institute of Technology. The award has attracted more

Extended Malaysian wound care tender

Bactiguard’s tender award for wound care products for the public sector in Malaysia has been extended by another year and the volume has increased. This enables healthcare providers in both primary and secondary care to purchase Bactiguard’s Wound Care system for infection prevention.“The public sector in Malaysia has consumed almost half a million bottles of our wound care products during the past five years with very positive outcome. Therefore, the Ministry of Health has extended the contract by another year with and increased the volume by 20 precent, which clearly shows that it adds

AcouSort: Interim Report 2021-04-01 – 2021-06-30

Second quarter (2021-04-01 – 2021-06-30) • Income amounted to TSEK 530 (1 448) • Result before tax amounted to TSEK -3 476 (-1 338) • Result per share was SEK -0,31 (-0,12) • Equity ratio amounted to 45 % (86 %) on 30 June 2021CEO Comments AcouSort has continued to develop well during the second quarter of the year. Our strategic collaborations continue to expand in the right direction. At the same time, interest in understanding and exploring our technology is growing and interest from the life science industry remains high strengthening our strategic investments in the OEM

Scandinavian ChemoTech AB (publ) Interim report Q2 January – June 2021 - Executive Summary of the second quarter

Second quarter · Net sales amounted to kSEK 5 (0) · Profit before tax amounted to kSEK - 3 796 (-2 557) · Earnings per share amounted to SEK -0,44 (-0,61) · Cash flow from operating activities totaled to kSEK -850 (-1 745) · The order book amounted to kSEK 1 122 (596) at the end of the quarter Period 1 January - 30 June · Net sales amounted to kSEK 30 (90) · Profit before tax amounted to kSEK -6 581 (-6 021) · Earnings per share amounted to SEK -0,81 (-1,59) · Cash flow from operating activities totaled to kSEK -6 414 (-5 865) · The order book amounted

First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the US Patent and Trademark Office (USPTO) will grant the company’s patent US11,103,481 directed to the use of SCO-101, on August 31, 2021.The granted patent covers combination therapy with Scandion Oncology’s first-in-class lead candidate SCO-101 and is part of the company’s patent family originating from the international application PCT/EP2017/061823. The patent claims the use of SCO-101 in combination with different anti-cancer agents across many cancer indications. The Patent Term for the US patent has been

Invitation to a webinar about Crunchfish’s half-year report for Q2 and first six months 2021

On Thursday, August 26 at 08:30 CEST/12:00 IST, Crunchfish AB (“Crunchfish”) publishes its half-year report for Q2 and first six months 2021. At 09:00 CEST / 12:30 IST, a live webinar about the report will be hosted on Zoom together with Alf Riple from Västra Hamnen Corporate Finance.In order to participate at this webinar, registration is done via the following link:https://us02web.zoom.us/webinar/register/WN_lRVT980CSROmai8XpK3TKw A recording of this webinar will also be available afterwards on Crunchfish’s website  as well as Västra Hamnen Corporate

Dustin's rights issue fully subscribed

The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Singapore or any other jurisdiction where such publication or distribution would violate applicable laws or regulations. See the section "Important information" at the end of this press release. The result of the rights issue in Dustin Group AB (publ) ("Dustin") shows that 16,064,052 shares have been subscribed for by the exercise of subscription rights. The remaining 95,773 shares have been allotted to

Talkpool Interim Report, January - June 2021

[][][][] April 1[st] – Jun Jan 1[st] – Jun 30[th] 202130[th] 2021 · Net sales amounted to EUR 11 937 thousand · Net sales amounted (9 770), a 22.2 percent increaseto EUR 6 246 thousand · EBITDA of EUR 432 thousand (188)(4 889), a 27.8 and EBITDA margin of 3.6 percent (1.9)percent increase · EBIT of EUR 238 thousand (-5) · EBITDA of EUR 383 and EBIT margin of 2 percent (-0.1)thousand (183) · Net earnings after tax of negativeand EBITDA margin of EUR 320 thousand (-791)6.1 percent (3.7) · EBIT of EUR 286

2020 Bulkers Ltd. (2020) - Conversion of index-linked charter hire for Bulk Sandefjord and Bulk Shanghai

Hamilton, Bermuda, August 25, 2021 2020 Bulkers has today converted the index-linked charters for Bulk Sandefjord and Bulk Shanghai into fixed rate charters at US$54,000 per ship per day, gross, for the period from September 1, 2021 until December 31, 2021. In addition, both vessels will still earn a premium related to the fuel cost savings from the scrubbers. The Company expects average operating cash breakeven after G&A, vessel operating costs and debt service of approximately US$14,500 per ship per day for 2021.   For further queries, please contact:  Magnus Halvorsen, Chief

FluoGuide A/S publishes interim report for the period January – June 2021

Copenhagen, Denmark, 25 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 June 2021. The H1 report is available as an attached document to this press release and on FluoGuide’s website.[][]Summary Q2 2021 Q2 2020 H1 2021 H1 2020 2020 01/Apr/21 01/Apr/20 01/Jan/21 01/Jan/20 01/Jan/20(KDKK) 30/Jun/21 30/Jun/20 30/Jun/21 30/Jun/20 31/Dec/20Net Revenue  0 0 0 0 0Operating -6,034 -6,583 -10,233 -10,506 -22,

Wicket Gaming adopts an acquisition strategy and raises previously communicated targets

August 25[th], 2021, 08:15 Today, August 25[th], Wicket Gaming AB (“Wicket Gaming” or the “Company”) published its interim report for the second quarter of 2021. In connection with this Eric de Basso, CEO of Wicket Gaming, chose to give an update in the report regarding new shareholders, the target for Cricket Manager, game number two and the new acquisition strategy.Comments in the report can be found in full in the Q2-report. The comments can be summarized as follows: New shareholders ”Once again, I would like to welcome all new shareholders to Wicket Gaming. With great

Adverty establishes local presence in Turkey, as Istanbul emerges as the hottest new gaming and tech hub in Europe

Adverty AB (publ) announces today a strategic positioning into Turkey with two new hires, to increase its presence in one of the largest, most exciting and fastest growing gaming communities in the world.Adverty, the leading in-game platform for advertisers, media agencies and game developers, has established local presence in Istanbul, with two new hires, a Director of Programmatic Sales and a Director of Publisher Growth, as the city emerges as the largest gaming hub for Europe, boasting a wide collection of gaming studios and unicorns. Turkey is rapidly becoming a star of European

AlzeCure publishes its interim report for January – June 2021

Stockholm, Sweden, August 25, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – June 2021 is now available on the company’s website: www.alzecurepharma.se/en/section/investors/financial-reports/“The AlzeCure team continues to make good progress according to plan, in high-profile areas that are becoming increasingly relevant, such as the US Food and Drug Administration’s (FDA) approval of a new drug for Alzheimer’s disease, the first in 18 years, which is expected to boost interest in the Alzheimer’s field. During the second

I-Tech AB (publ) Interim report Q2 2021

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the second quarter 2021 Click here on the 25 August 2021 at 10:00 to follow the webcast Summary of the period” Positive key events in a challenging business cycle ” •    Net turnover for the period amounted to 12 819 (16 150) kSEK, corresponding to a decrease inturnover of -21% (28%). Operating profit/loss amounted to -3 192 (47) kSEK.April to June 2021•    Chugoku Marine Paints launched SEAFLO NEO M1 PLUS, another global Selektope®-powered antifouling paint.•    I-Tech

Orthex H1: Strong growth in all markets and categories, high raw material price level continues

Orthex Corporation, Stock exchange release, August 25, 2021 at 9.00 a.m. EEST This release is a summary of Orthex Corporation’s Half Year Financial Report January–June 2021. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/.   January–June 2021 in Brief · Invoiced sales increased by 27.9% and totalled EUR 45.0 million (35.2) · Net sales increased by 28.8% to EUR 43.8 million (34.0) · Adjusted EBITDA was EUR 7.8 million (7.2) (adjusted for IPO related costs EUR 1.5 million) ·

Vestas secures 50 MW in two Polish projects

News release from Vestas Northern & Central EuropeHamburg, 25 August 2021 Vestas has received two orders in Poland totalling 50 MW from the Project Joint Venture between V-Ridium Power Group and KGAL. V-Ridium is fully owned by Greenvolt – Energias Renovaveis SA, while KGAL is a leading independent investment and asset manager with assets under management of around €11.2 billion and assets under administration of €4.0 billion. The order is to supply and install turbines at the 15 MW Podlasek and 35 MW Wólka Dobryńska projects in Poland, both targeted for full commissioning by the

Polymer Factory Sweden AB (publ) Interim Report Q2 2021

The period in summary Second quarter, April-June 2021 · The company was listed on Spotlight Stock Market with first day of trading 7th April 2021. · A new CEO started 1st April 2021. · The loss for the period amounted to KSEK -922, of which KSEK 200 can be derived from IPO related activities. · Net sales for the period increased with 177% Q2. Year to date, January-June 2021 · The operating loss for the period amounted to KSEK -1,414, of which KSEK 691 can be derived from IPO related activities. · Net sales for the period increased with 121% for year-to-date.

Glycorex Transplantation AB (GTAB): Interim Report April-June 2021

Net sales increased 143% and significantly improved operating income.April – June 2021 (compared to the corresponding period last year) · Net sales: SEK 8,0 million (3,3). · Operating income: SEK -2,2 million (-6,4). · Net income for the period: SEK -2,3 million (-6,8). · Earnings per share: SEK -0,03 (-0,09), no dilution effects. · COVID-19 reorientation support SEK 0,85 million received. · Positive trend and good sales growth in the majority of the company's markets, including record sales to Spain and 74 percent growth in the company's largest market Germany.

Interim report January–June 2021

The Battery Sensors and Instruments business areas take a concerted approach to electric vehicles• Board and organization strengthened. Outcome April–June• Net sales amounted to kSEK 492 (335).• Profit after net financial items amounted to kSEK –3,638 (–3,234).• Basic and diluted earnings per share: SEK –0.28 (–0.33).• Cash flow from operating activities and investing activities: kSEK –1,678 (980). Significant events April–June• Insplorion’s annual general meeting was held on April 19th where Magnus Jonsson was elected as a new member of the board.• The annual general

Hansa Biopharma achieves Great Place to Work certification for second consecutive year

· Award granted by internationally recognized Great Place to Work institute · Based on company-wide survey completed by all Hansa employees and review of company HR policies · Metrics reflective of trust in the company, such as credibility, pride and fairness, were among those most highly rated by employees                Lund, Sweden, August 25, 2021. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced its certification as a Great Places to Work 2021. The accolade was awarded by the independent

First Patient Dosed in Phase II/III COVID-19 Trial

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial of Traumakine for Treatment of Hospitalized COVID-19 Patients ·Trial co-funded by US Department of Defense Company announcement, August 25, 2021 at 9.00 AM (EEST)Inside information TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today

InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021

First regulatory approvals to start the phase III study CONCLUDE“We will initiate patient recruitment when the clinics are up and running again after the summer as the healthcare situation has started to normalise,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period April – June 2021 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –42.6 (–15.6) million · Result after tax amounted to SEK –42.6 (–15.6) million, corresponding to SEK –0.08 per share (–0.07) before and after dilution · Cash flow from operating activities amounted to SEK –53.

Talkpool Germany signs frame agreements worth EUR 1.025 million

Talkpool Germany has won framework agreements for network planning and documentation worth EUR 1.025 million from one of the leading telecom operators in Germany. The term extends into the 3rd quarter of 2023 and the frame agreement does not state certain order volumes for specific time periods. Talkpool is thus further expanding its market presence and range of services in Germany. This now extends far beyond the planning and documentation of classic copper cable house connections to network planning and documentation of fiber optic house connections for private households, schools,

There are no items matching the current filter
There are no more items matching the current filter
Back to top